anti-Progesterone Receptor (PGR) antibody

anti-Progesterone Receptor (PGR) antibody: The determination of steroid hormone receptors is of great importance for therapy of patients with hormone receptor expressing tumours. Expression of progesterone receptors in tumour cells of human breast carcinoma points to an intact estrogen receptor and to sensitivity of this tumour to endocrine therapy. The progesterone receptor content is therefore a marker for response to hormone therapy. The method mainly used for determination of hormone receptors is immunohistochemistry. Progesterone and estrogen receptor positive breast carcinoma patients have demonstrated a better response to endocrine therapy than receptor negative patients. Therefore, steroid hormone receptors are positive prognostic factors. Use of monoclonal antibodies for determination of receptor status increases the predictive value concerning response to the therapy. Immunohistochemistry (IHC) is a complex technique in which immunological and histological detection methods are combined. In general, the manipulation and processing of tissues before immunostaining, especially different types of tissue fixation and embedding, as well as the nature of the tissues themselves may cause inconsistent results (Nadji and Morales, 1983). Endogenous pseudoperoxidase and peroxidase activity or endogenous biotin and alkaline phosphatase activity can cause non-specific staining results depending on the detection system used. Tissues that contain Hepatitis B surface antigen (HBsAg) can produce false positives when using HRP detection systems (Omata et al, 1980). Insufficient contrast staining and/or improper mounting of the sample may influence the interpretation of results.

Prices direct from Antibodies-online

Quick response times

Exclusive Biosave savings/discounts